Home / Publications / A novel molecular platform for co-delivery of monomethyl auristatin E and ispinesib to prostate cancer cells

A novel molecular platform for co-delivery of monomethyl auristatin E and ispinesib to prostate cancer cells

, 
Anastasiia Yuryevna Kolchanova 1
Anastasiia Yuryevna Kolchanova
, 
Natalya Sergeevna Volkova 1
Natalya Sergeevna Volkova
, 
Anastasiia Alekseevna Uspenskaia 1
Anastasiia Alekseevna Uspenskaia
, 
Dmitry Aleksandrovich Skvortsov 1
Dmitry Aleksandrovich Skvortsov
, 
Elena Kimovna Beloglazkina 1
Elena Kimovna Beloglazkina
, 
Nikolai Vasil'evich Zyk 1
Nikolai Vasil'evich Zyk
, 
Alexander Georgievich Majouga 2
Alexander Georgievich Majouga
, 
Aleksei Eduardovich Machulkin 1, 3
Aleksei Eduardovich Machulkin
10.71267/mencom.7661
Published 2025-05-21
Communication , Volume 35, Issue 4, 440-443
0
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Zyk N. Y. et al. A novel molecular platform for co-delivery of monomethyl auristatin E and ispinesib to prostate cancer cells // Mendeleev Communications. 2025. Vol. 35. No. 4. pp. 440-443.
GOST all authors (up to 50) Copy
Zyk N. Y., Kolchanova A. Y., Volkova N. S., Uspenskaia A. A., Skvortsov D. A., Beloglazkina E. K., Zyk N. V., Majouga A. G., Machulkin A. E. A novel molecular platform for co-delivery of monomethyl auristatin E and ispinesib to prostate cancer cells // Mendeleev Communications. 2025. Vol. 35. No. 4. pp. 440-443.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.71267/mencom.7661
UR - https://mendcomm.colab.ws/publications/10.71267/mencom.7661
TI - A novel molecular platform for co-delivery of monomethyl auristatin E and ispinesib to prostate cancer cells
T2 - Mendeleev Communications
AU - Zyk, Nikolay Yurievich
AU - Kolchanova, Anastasiia Yuryevna
AU - Volkova, Natalya Sergeevna
AU - Uspenskaia, Anastasiia Alekseevna
AU - Skvortsov, Dmitry Aleksandrovich
AU - Beloglazkina, Elena Kimovna
AU - Zyk, Nikolai Vasil'evich
AU - Majouga, Alexander Georgievich
AU - Machulkin, Aleksei Eduardovich
PY - 2025
DA - 2025/05/21
PB - Mendeleev Communications
SP - 440-443
IS - 4
VL - 35
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Zyk,
author = {Nikolay Yurievich Zyk and Anastasiia Yuryevna Kolchanova and Natalya Sergeevna Volkova and Anastasiia Alekseevna Uspenskaia and Dmitry Aleksandrovich Skvortsov and Elena Kimovna Beloglazkina and Nikolai Vasil'evich Zyk and Alexander Georgievich Majouga and Aleksei Eduardovich Machulkin},
title = {A novel molecular platform for co-delivery of monomethyl auristatin E and ispinesib to prostate cancer cells},
journal = {Mendeleev Communications},
year = {2025},
volume = {35},
publisher = {Mendeleev Communications},
month = {May},
url = {https://mendcomm.colab.ws/publications/10.71267/mencom.7661},
number = {4},
pages = {440--443},
doi = {10.71267/mencom.7661}
}
MLA
Cite this
MLA Copy
Zyk, Nikolay Yurievich, et al. “A novel molecular platform for co-delivery of monomethyl auristatin E and ispinesib to prostate cancer cells.” Mendeleev Communications, vol. 35, no. 4, May. 2025, pp. 440-443. https://mendcomm.colab.ws/publications/10.71267/mencom.7661.

Keywords

azide–alkyne cycloaddition
bimodal conjugates
ispinesib
monomethyl auristatin E
peptide synthesis
prostate cancer
prostate specific membrane antigen

Abstract

A conjugate for co-delivery of ispinesib and monomethyl auristatin E was prepared using methods of peptide synthesis and azide–alkyne cycloaddition. Cytotoxicity studies of the mentioned drug pair were performed. In vitro studies of the synthesized bimodal conjugate were conducted on prostate cancer cell lines.

Funders

Russian Science Foundation
24-23-00156

References

1.
Nanohybride materials based on magnetite-gold nanoparticles for diagnostics of prostate cancer: Synthesis and in vitro testing
Machulkin A.E., Garanina A.S., Zhironkina O.A., Beloglazkina E.K., Zyk N.V., Savchenko A.G., Kotelyanskii V.E., Mazhuga A.G.
Bulletin of Experimental Biology and Medicine, 2016
2.
Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them
Machulkin A.E., Shafikov R.R., Uspenskaya A.A., Petrov S.A., Ber A.P., Skvortsov D.A., Nimenko E.A., Zyk N.U., Smirnova G.B., Pokrovsky V.S., Abakumov M.A., Saltykova I.V., Akhmirov R.T., Garanina A.S., Polshakov V.I., et. al.
Journal of Medicinal Chemistry, 2021
3.
Synthesis and Biological Analysis of Prostate-Specific Membrane Antigen-Targeted Anticancer Prodrugs
Kularatne S.A., Venkatesh C., Santhapuram H.R., Wang K., Vaitilingam B., Henne W.A., Low P.S.
Journal of Medicinal Chemistry, 2010
4.
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy
Wester H., Schottelius M.
Seminars in Nuclear Medicine, 2019
5.
Development of novel PLGA nanoparticles with co‐encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells
Sokol M.B., Nikolskaya E.D., Yabbarov N.G., Zenin V.A., Faustova M.R., Belov A.V., Zhunina O.A., Mollaev M.D., Zabolotsky A.I., Tereshchenko O.G., Severin E.S.
Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2018
6.
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Eder M., Schäfer M., Bauder-Wüst U., Hull W., Wängler C., Mier W., Haberkorn U., Eisenhut M.
Bioconjugate Chemistry, 2012
8.
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
Weineisen M., Schottelius M., Simecek J., Baum R.P., Yildiz A., Beykan S., Kulkarni H.R., Lassmann M., Klette I., Eiber M., Schwaiger M., Wester H.
Journal of Nuclear Medicine, 2015
9.
PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation
Machulkin A.E., Uspenskaya A.A., Zyk N.Y., Nimenko E.A., Ber A.P., Petrov S.A., Shafikov R.R., Skvortsov D.A., Smirnova G.B., Borisova Y.A., Pokrovsky V.S., Kolmogorov V.S., Vaneev A.N., Ivanenkov Y.A., Khudyakov A.D., et. al.
European Journal of Medicinal Chemistry, 2022
10.
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin e Conjugate
Machulkin A.E., Uspenskaya A.A., Zyk N.U., Nimenko E.A., Ber A.P., Petrov S.A., Polshakov V.I., Shafikov R.R., Skvortsov D.A., Plotnikova E.A., Pankratov A.A., Smirnova G.B., Borisova Y.A., Pokrovsky V.S., Kolmogorov V.S., et. al.
Journal of Medicinal Chemistry, 2021
11.
Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia
Bregante J., Schönbichler A., Pölöske D., Degenfeld-Schonburg L., Monzó Contreras G., Hadzijusufovic E., de Araujo E.D., Valent P., Moriggl R., Orlova A.
Cancers, 2021
12.
Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
Wang Z., Dai Z., Wang B., Gao Y., Gao X., Wang L., Zhou S., Yang L., Qiu X., Liu Z.
OncoTargets and Therapy, 2021
14.
Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer
Purcell J.W., Davis J., Reddy M., Martin S., Samayoa K., Vo H., Thomsen K., Bean P., Kuo W.L., Ziyad S., Billig J., Feiler H.S., Gray J.W., Wood K.W., Cases S., et. al.
Clinical Cancer Research, 2010
15.
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
Blagden S.P., Molife L.R., Seebaran A., Payne M., Reid A.H., Protheroe A.S., Vasist L.S., Williams D.D., Bowen C., Kathman S.J., Hodge J.P., Dar M.M., de Bono J.S., Middleton M.R.
British Journal of Cancer, 2008
16.
Synthesis and Preclinical Evaluation of Small-Molecule Prostate-Specific Membrane Antigen-Targeted Abiraterone Conjugate
Machulkin A.E., Nimenko E.A., Zyk N.U., Uspenskaia A.A., Smirnova G.B., Khan I.I., Pokrovsky V.S., Vaneev A.N., Timoshenko R.V., Mamed-Nabizade V.V., Zavertkina M.V., Erofeev A., Gorelkin P., Majouga A.G., Zyk N.V., et. al.
Molecules, 2022
20.
Co-delivery of Docetaxel and Resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer
Zhang L., Lin Z., Chen Y., Gao D., Wang P., Lin Y., Wang Y., Wang F., Han Y., Yuan H.
European Journal of Pharmaceutical Sciences, 2022
21.
Synthesis of Prostate-Specific Membrane Antigen-Targeted Bimodal Conjugates of Cytotoxic Agents and Antiandrogens and Their Comparative Assessment with Monoconjugates
Zyk N.Y., Garanina A.S., Plotnikova E.A., Ber A.P., Nimenko E.A., Dashkova N.S., Uspenskaia A.A., Shafikov R.R., Skvortsov D.A., Petrov S.A., Pankratov A.A., Zyk N.V., Majouga A.G., Beloglazkina E.K., Machulkin A.E., et. al.
International Journal of Molecular Sciences, 2023
22.
Zyk N.Y., Petrov S.A., Zavertkina M.V., Uspenskaya A.A., Krasnikov P.A., Dashkova N.S., Beloglazkina E.K., Majouga A.G., Zyk N.V., Machulkin A.E.
Mendeleev Communications, 2023
23.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A.
Ca-A Cancer Journal for Clinicians, 2024